Repaglinide glucose oscillation study in Fukuoka

Repaglinide glucose oscillation study in Fukuoka - REGO-F

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018321

Enrollment

120

Registered

2015-07-15

Start date

2015-06-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

Repaglinide 0.5mg X 3 Glimepiride 1mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, Type 2 Diabetes 2, Patients who has been treated with standerd dose of DPP-4 inhibitors for 12 weeks 3, 6%~HbA1c<9%

Exclusion criteria

Exclusion criteria: Patients with contra-indication of sulfonylureas or glinides

Design outcomes

Primary

Measure	Time frame
Glucose oscillation monitored by CGM	—

Secondary

Measure	Time frame
Cervical IMT	—

Countries

Japan

Contacts

Public ContactTakashi Nomiyama

Fukuoka university, school of medicine Department of endocrinology and diabetes mellitus

tnomiyama@fukuoka-u.ac.jp092-801-1011

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026